Verster Joris C, Dahl Thomas A, Scholey Andrew, Iversen Jacqueline M
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands.
Institute for Risk Assessment Sciences (IRAS), Utrecht University, 3584CM Utrecht, The Netherlands.
J Clin Med. 2020 Mar 31;9(4):932. doi: 10.3390/jcm9040932.
Despite a clear market need and many hangover products available, currently there is no hangover treatment that is supported by substantial scientific evidence demonstrating its efficacy and safety. A pilot study was conducted to investigate the effects of a potential new hangover treatment, SJP-001, and its constituents (220 mg naproxen and 60 mg fexofenadine) on hangover severity.
= 13 healthy social drinkers (36.3 ± 8.9 years old) participated in a double-blind, factorial design, cross-over study. On each test day, they consumed their own choice of alcohol up to a self-reported level sufficient to elicit a next-day hangover. Treatments were administered prior to onset of drinking. Next morning, hangover severity was assessed with the Acute Hangover Scale (AHS). Subjects were included in the efficacy analysis only if they reported a hangover after placebo.
= 5 subjects (60% male, 35.2 ± 9.0 years old) were included in the analysis. They consumed a mean (SD) of 4.6 ± 1.1 units of alcohol and had an average peak breath alcohol concentration (BrAC) of 0.065% across conditions. Compared to placebo, SJP-001 significantly improved the AHS overall hangover severity score (0.8 ± 0.3 versus 1.5 ± 0.9, = 0.042). Compared to placebo, SJP-001 also reduced scores on the individual item 'hangover', although the observed improvement (-1.6) did not reach statistical significance ( = 0.102). The differences from placebo after naproxen alone and fexofenadine alone were not statistically significant. SJP-001 also improved scores for the individual hangover symptoms tired, thirsty, headache, dizziness, nausea, and loss of appetite, but these effects did not reach statistical significance.
Compared to placebo, SJP-001 significantly reduced overall hangover severity. The effects of SJP-001 should be further examined in a double-blind, placebo-controlled trial with a larger sample size and controlled administration of sufficient amounts of alcohol to provoke a more substantial alcohol hangover.
尽管市场有明确需求且有多种解酒产品可供选择，但目前尚无大量科学证据支持其有效性和安全性的解酒疗法。开展了一项初步研究，以调查一种潜在的新型解酒疗法SJP - 001及其成分（220毫克萘普生和60毫克非索非那定）对宿醉严重程度的影响。
13名健康的社交饮酒者（36.3±8.9岁）参与了一项双盲、析因设计的交叉研究。在每个测试日，他们根据自己的选择饮酒，直至自我报告达到足以引发次日宿醉的程度。在饮酒开始前给予治疗。次日早晨，使用急性宿醉量表（AHS）评估宿醉严重程度。仅当受试者在服用安慰剂后报告有宿醉症状时，才纳入疗效分析。
5名受试者（60%为男性，35.2±9.0岁）纳入分析。他们在各种情况下平均饮用4.6±1.1个酒精单位，平均呼气酒精浓度峰值（BrAC）为0.065%。与安慰剂相比，SJP - 001显著改善了AHS总体宿醉严重程度评分（0.8±0.3对1.5±0.9，P = 0.042）。与安慰剂相比，SJP - 001也降低了“宿醉”单项得分，尽管观察到的改善（-1.6）未达到统计学显著性（P = 0.102）。单独使用萘普生和单独使用非索非那定与安慰剂相比的差异无统计学意义。SJP - 001还改善了个体宿醉症状疲劳、口渴、头痛、头晕、恶心和食欲不振的得分，但这些效果未达到统计学显著性。
与安慰剂相比，SJP - 001显著降低了总体宿醉严重程度。SJP - 001的效果应在一项双盲、安慰剂对照试验中进一步研究，该试验样本量更大，并控制给予足够量的酒精以引发更严重的酒精性宿醉。
